tbuckley/cabot-search huggingface dataset:
Mutual epithelium‐macrophage dependency in liver carcinogenesis mediated by ST18
Authors: Micol Ravà, Aleco D'Andrea, Mirko Doni, Theresia R. Kress, Renato Ostuni, Valerio Bianchi, Marco J. Morelli, Agnese Collino, Serena Ghisletti, Paola Nicoli, Camilla Recordati, Maria Iascone, Aurelio Sonzogni, Lorenzo D'Antiga, Ruchi Shukla, Geoffrey J. Faulkner, Gioacchino Natoli, Stefano Campaner, Bruno Amati
Journal: Hepatology (2016)

The ST18 gene has been proposed to act either as a tumor suppressor or as an oncogene in different human cancers, but direct evidence for its role in tumorigenesis has been lacking thus far. Here, we demonstrate that ST18 is critical for tumor progression and maintenance in a mouse model of liver cancer, based on oncogenic transformation and adoptive transfer of primary precursor cells (hepatoblasts). ST18 messenger RNA (mRNA) and protein were detectable neither in normal liver nor in cultured hepatoblasts, but were readily expressed after subcutaneous engraftment and tumor growth. ST18 expression in liver cells was induced by inflammatory cues, including acute or chronic inflammation in vivo, as well as coculture with macrophages in vitro. Knocking down the ST18 mRNA in transplanted hepatoblasts delayed tumor progression. Induction of ST18 knockdown in pre-established tumors caused rapid tumor involution associated with pervasive morphological changes, proliferative arrest, and apoptosis in tumor cells, as well as depletion of tumor-associated macrophages, vascular ectasia, and hemorrhage. Reciprocally, systemic depletion of macrophages in recipient animals had very similar phenotypic consequences, impairing either tumor development or maintenance, and suppressing ST18 expression in hepatoblasts. Finally, RNA sequencing of ST18-depleted tumors before involution revealed down-regulation of inflammatory response genes, pointing to the suppression of nuclear factor kappa B-dependent transcription.ST18 expression in epithelial cells is induced by tumor-associated macrophages, contributing to the reciprocal feed-forward loop between both cell types in liver tumorigenesis. Our findings warrant the exploration of means to interfere with ST18-dependent epithelium-macrophage interactions in a therapeutic setting. (Hepatology 2017;65:1708-1719).
Decrease of Serum TARC Levels As Predictive Biomarkers of Response to Targeted Therapy with Kinase Inhibitors in Refractory/Relapsed Hodgkin Lymphoma Patients
Authors: Anna Guidetti, Simonetta Viviani, Anna Dodero, Lucia Farina, Domenico Russo, Pietro Bulian, Massimo Di Nicola, Arabella Mazzocchi, Fernando Ravagnani, Paolo Corradini, Alessandro Massimo Gianni, Carmelo Carlo-Stella
Journal: Blood (2014)
THU0386 The Association of Serum Trail Levels and Metabolic Parameters in Patients with AS and PsA: Table 1
Authors: D. Temiz Karadağ, F.C. Eraldemir, Ö. Özdemir Işık, S. Tekeoğlu, A. Yazıcı, A. Cefle
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Tumour necrosis factor-related apoptosis-inducing ligand (TRAIL), is a pro-apoptotic, multi-functional cytokine.Several studies have suggested that autoimmun diseases, diabetes mellitus, hyperlipidemia and cardiovascular diseases were associated with circulating TRAIL concentrations. <h3>Objectives</h3> The aim of this study was to investigate, whether TRAIL levels were associated with metabolic features in patients with ankylosing spondylitis (AS) and psoriatic arthritis (PsA). <h3>Methods</h3> We compared the relationship between the serum levels of TRAIL with body mass index, waist circumference, fasting plasma glucose, insulin, HOMA, hemoglobin A1C, cholesterol levels in 53 patients with AS, 42 patients with PsA and 53 healthy controls. We also analysed the association ofTRAIL with inflammatory parameters (CRP, ESR, TNF-α)and disease acitivity (BASDAI, BASFI, DAS28-ESR). None of the patients included in this study had diabetes mellitus or CVD. <h3>Results</h3> Serum levels of TRAIL were not different in patients with PsA (5,06±3,23 pg/ml), AS (4,36±2,49 pg/ml) and HC (3,85±2,2 pg/ml, <i>p=0,155</i>).Serum TRAIL had a direct and significant correlation with waist circumference (<i>p=0,005</i>), TNF-α (<i>p=0,000</i>) and CRP (<i>p=0,021</i>).When we analysed the results in patients with AS;serum TRAIL levels directly correlated with TNF-α (<i>p=0,003</i>),LDL (<i>p=0,041</i>) and total cholesterol (<i>p=0,026</i>).Serum TRAIL levels were higher in HLAB-27 positive patients than negative patients (<i>p=0,001</i>). TNF-α levels were higher in AS than PsA and healthy controls (<i>p=0,038</i>).TNF-α was inversely associated with BASDAI (<i>p=0,029</i>) and BASFI (<i>p=0,046</i>). <h3>Conclusions</h3> Our results showed that, serum TRAIL levels were associated with TNF-α, LDL-cholesterol and total cholesterol in patients with AS.Serum TRAIL concentrations were higher in HLAB-27 positive patients.Further studies are needed to clarify the underlying basis, because it seems there is a complex interaction between inflammatory processes and metabolic disorders. <h3>References</h3> G.Zauli and P.Secchiero, The role of the TRAIL/TRAIL receptors system in hematopoiesis and endothelial cell biology. Cytokine and Growth Factor Reviews,vol.17,no.4,pp.245–257,2006. Harith HH DiBartolo BA,Insulin promotes VSMC proliferation and apoptosis via differential regulation of TNF-related apoptosis inducing ligand. JDiabetes.2015 doi:10.1111/1753-0407. <h3>Disclosure of Interest</h3> None declared
OP0280 Improved Survival in Giant Cell Arteritis: A Population-Based Study: Table 1.
Authors: L.M. Belvedere, H.K. Choi, N. Dehghan, E.C. Sayre, J.A. Avina-Zubieta
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Giant cell arteritis (GCA) is associated with significant morbidity and mortality, but previous studies on mortality in GCA have yielded conflicting results. Furthermore, mortality trends are largely unknown, particularly in the general population. <h3>Objectives</h3> To address this knowledge gap, we evaluated mortality trends in individuals with GCA in a general population-context from January 1, 1997 – December 31, 2012. <h3>Methods</h3> Using an administrative health database from the province of British Columbia, Canada (population approximately 4.5 million), we identified all incident cases of GCA and up to 10 non-GCA sex-, age- and entry-time-matched controls. The case definition for GCA included at least one prescription of oral glucocorticoids between one month before and six months after the index date. Study cohorts were divided into two sub-groups based on the year of diagnosis (i.e., 1997–2004 and 2005–2012). Mortality rates were calculated, as well as hazard ratios (HR) using a Cox proportional hazard model. HRs were adjusted for potential confounders (e.g., Charlson9s comorbidity index, number of outpatient visits and hospitalizations, cardiovascular drugs, glucocorticoids, cox-2 inhibitors, NSAIDs within 12 months prior to index date). <h3>Results</h3> The early cohort (i.e., 1997–2004) of GCA patients had considerably higher mortality rates than the late cohort (i.e., 2005–2012) (i.e., 373.7 vs 87.5 cases per 1000 person-years), while the non-GCA cohort experienced a much smaller improvement in mortality rates between the two time periods (i.e., 70.9 vs 52.0 cases per 1000 person-years). The resulting HRs for mortality for the early and late cohorts were 4.58 (95% CI, 3.70–5.67) and 1.46 (95% CI, 1.16–1.84), respectively. Testing for difference between incident cohorts via an interaction term were all significant. <h3>Conclusions</h3> This population-based study shows that survival of GCA patients has improved in recent years, suggesting that new treatment strategies and improved management of GCA and its associated complications has led to significant improvements in GCA-associated mortality. <h3>Acknowledgement</h3> This study was funded by the Canadian Arthritis Network, The Arthritis Society of Canada/the British Columbia Lupus Society (Grant 10-SRP-IJD-01) and The Canadian Institutes of Health Research (THC-135235). <h3>Disclosure of Interest</h3> None declared
Molecular Response to First Line Imatinib Therapy Is Predictive for Long Term Event Free Survival in Patients with Chronic Phase Chronic Myelogenous Leukemia – An Interim Analysis of the Randomized German CML Study IV
Authors: Martin C. Müller, Benjamin Hanfstein, Philipp Erben, Susanne Schnittger, Susanne Saussele, Armin Leitner, Ulrike Proetel, Michael Lauseker, Markus Pfirrmann, Gerhard Ehninger, Thomas Fischer, Joerg Hasford, Dieter K. Hossfeld, Hans Jochem Kolb, Stefan W Krause, Christoph Nerl, Hans Pralle, Alois Gratwohl, Andreas Tobler, Ruediger Hehlmann, Andreas Hochhaus
Journal: Blood (2008)
Prevalence of Depression in Patients With Mild Cognitive Impairment
Authors: Zahinoor Ismail, Heba Elbayoumi, Corinne E. Fischer, David B. Hogan, Colleen P. Millikin, Tom Schweizer, Moyra E. Mortby, Eric E. Smith, Scott B. Patten, Kirsten M. Fiest
Journal: JAMA Psychiatry (2016)

Depression is common in individuals with mild cognitive impairment (MCI) and may confer a higher likelihood of progression to dementia. Prevalence estimates of depression in those with MCI are required to guide both clinical decisions and public health policy, but published results are variable and lack precision.To provide a precise estimate of the prevalence of depression in individuals with MCI and identify reasons for heterogeneity in the reported results.A search of literature from database inception to March 2016 was performed using Medline, Embase, and PsycINFO. Hand searching of all included articles was performed, including a Google Scholar search of citations of included articles.Articles were included if they (1) were published in English, (2) reported patients with MCI as a primary study group, (3) reported depression or depressive symptoms using a validated instrument, and (4) reported the prevalence of depression in patients with MCI.All abstracts, full-text articles, and other sources were reviewed, with data extracted in duplicate. The overall prevalence of depression in patients with MCI was pooled using a random-effects model. Heterogeneity was explored using stratification and random-effects meta-regression.The prevalence of depression in patients with MCI, reported as a percentage with 95% CIs. Estimates were also stratified by population source (community-based or clinic-based sample), method of depression diagnosis (clinician-administered, informant-based, or self-report), and method of MCI diagnosis (cognitive vs global measure and amnestic vs nonamnestic).Of 5687 unique abstracts, 255 were selected for full-text review, and 57 studies, representing 20 892 patients, met all inclusion criteria. The overall pooled prevalence of depression in patients with MCI was 32% (95% CI, 27-37), with significant heterogeneity between estimates (I2 = 90.7%). When stratified by source, the prevalence of depression in patients with MCI in community-based samples was 25% (95% CI, 19-30) and was 40% (95% CI, 32-48) in clinic-based samples, which was significantly different (P < .001). The method used to diagnose depression did not significantly influence the prevalence estimate, nor did the criteria used for MCI diagnosis or MCI subtype.The prevalence of depression in patients with MCI is high. A contributor to heterogeneity in the reported literature is the source of the sample, with greater depression burden prevalent in clinic-based samples.
Serum CD26 (Dipeptidyl Peptidase IV, DPP IV) compared with Immunoglobulin Heavy-Chain Mutation Status, ZAP-70 and CD38 as a Predictor of Time to First Treatment in Early B-CELL Chronic Lymphocytic Leukemia
Authors: Stefano Molica, Gaetano Vitelli, Giovanna Cutrona, Rosanna Mirabelli, Giovanna Digiesi, Diana Giannarelli, Isabella Sperduti, Fortunato Morabito, Manlio Ferrarini
Journal: Blood (2008)
FRI0402 Quantification of Fat Fraction of Vertebral Bone Marrow in Patients with Ankylosing Spondylitis
Authors: S. Lee, Y. Song, B.S. Koo, T.-H. Kim
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Focal fat deposition is frequently seen on magnetic resonance imaging (MRI) of the spine in patients with ankylosing spondylitis (AS)<sup>1</sup>. Fat metaplasia in bone marrow is known as one of disease progression in AS<sup>2</sup>. <h3>Objectives</h3> To evaluate clinical characteristics and the correlation between bone marrow fat-signal fraction (FF), Bath AnkylosingSpondylitis Disease Activity Index (BASDAI), Bath AnkylosingSpondylitis Functional Index (BASFI) and modified Stoke Ankylosing Spondylitis Spine Score (mSASSS). <h3>Methods</h3> A total of 55 patients with AS who underwent a spine MRI at our institution from March 2015 to December 2015 were retrospectively evaluated. Quantification of vertebral bone marrow was assessed on the FF maps using the three-point Dixon technique<sup>3</sup>. FF was quantified after measuring the signal intensity within the region of interest (ROI) over anterosuperior and anteroinferior corner of bone marrow where there was no contamination from the bony cortex or syndesmophyte. The ROIs were drawn twice in sagittal FF map and average was used. mSASSSs were independently recorded by two musculoskeletal radiologists. Correlation, univariate and multivariate regression analyses were done for identifying significant predictors of FF. <h3>Results</h3> Patients had a mean age of 35.6±10.5 years, and 43 were male (78.2%). A significant correlation was found between FF, mSASSS, BASDAI, and BASFI (p=0.005, p=0.021, and p=0.050)in Pearson correlation analysis. Multivariate regression analysis showed that decrease total BASDAI associated with to increase FF (p=0.005). Measurements of mSASSS had excellent intraobserver (mean intraclass correlation coefficient [ICC] = 0.997 [95% confidence interval (CI): 0.994–0.999] and interobserver agreement (mean ICC =0.941–0.995).However, erythrocyte sedimentation rate (ESR) and C reactive protein (CRP) did not correlated with FF. <h3>Conclusions</h3> The quantitative assessment of FF using MRI might be another useful novel imaging technique to correlateactivity index of AS. <h3>References</h3> Chiowchanwisawakit, P., Lambert, R. G., Conner-Spady, B. &amp; Maksymowych, W. P. Focal fat lesions at vertebral corners on magnetic resonance imaging predict the development of new syndesmophytes in ankylosing spondylitis. Arthritis and rheumatism, 2215–2225, doi:10.1002/art.30393 (2011). Maksymowych, W. P., Wichuk, S., Chiowchanwisawakit, P., Lambert, R. G. &amp; Pedersen, S. J. Fat metaplasia and backfill are key intermediaries in the development of sacroiliac joint ankylosis in patients with ankylosing spondylitis. Arthritis &amp; rheumatology, 2958–2967, doi:10.1002/art.38792 (2014). Eggers, H., Brendel, B., Duijndam, A. &amp; Herigault, G. Dual-echo Dixon imaging with flexible choice of echo times. Magnetic resonance in medicine, 96–107, doi:10.1002/mrm.22578 (2011). <h3>Disclosure of Interest</h3> None declared
Engineered Factor IX with Augmented Clotting Activities in a Hemophilia B Mouse Model.
Authors: Chia-Ni Lin, Chung-Yang Kao, Chia-Lun Hong, Peiqing Ye, Carol H. Miao, Nobuko Hamaguchi, Hua-Lin Wu, Guey-Yueh Shi, Yung-Li Yang, I-Shing Yu, Mi-Hua Tao, Cheng-Chieh Fang, Yi-Lin Liu, Katherine A. High, Shu-Wha Lin
Journal: Blood (2008)
Comprehensive Workup of Myelodysplastic Syndromes: Comparing Targeted DNA Sequencing, Oligo/SNP Microarray and Higher Dimensional Flow Cytometry.
Authors: Marilyn L Slovak, Ya-Hsuan Hsu, Hseuh-Hua Chen, Yongbao Wang, Philip N Mowrey, Charles Repetti, Albert K Ho, Qiulu Pan, Ila Bansal, Dan Jones
Journal: Blood (2012)
Focusing on Core Patient-Reported Outcomes in Cancer Clinical Trials—Letter
Authors: Mogens Groenvold, Neil K. Aaronson, Anne-Sophie E. Darlington, Deborah Fitzsimmons, Eva Greimel, Bernhard Holzner, Jaap C. Reijneveld, Krzysztof A. Tomaszewski, Irma Verdonck-de Leeuw, Lonneke van de Poll-Franse
Journal: Clinical Cancer Research (2016)

Kluetz and colleagues from the FDA ([1][1]) provide a welcome overview of the challenges related to patient-reported outcomes assessment in cancer clinical trials seen from a regulatory perspective.

The article raises a relevant issue in the current era of novel therapies and associated unique
FRI0453 The Increased Prevalence of Nafld Is Worrisome among Patients with Psoriatic Arthritis
Authors: C. Gaspari, G. Carvalho, L. Anjos, P. Sampaio-Barros, J. Moraes, C. Gonçalves, C. Saad, C. Goldenstein-Schainberg
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Non-alcoholic fatty liver disease (NAFLD) affects 20–30% of general population and a wide range of 14–59% patients with cutaneous psoriasis (PsO). Psoriatic arthritis (PsA) has been linked to comorbidities including diabetes, arterial hypertension, dyslipidemia and metabolic syndrome (MetS) though data on NAFLD in PsA is lacking. In fact, in PsA, NAFLD has been evaluatedin only one Italian study affecting 28% patients. <h3>Objectives</h3> To evaluate the prevalence of NAFLD in our cohort of patients with PsA. <h3>Methods</h3> All patients with PsA regularly followed-up during a 6 month period at our outpatient rheumatology clinic were studied. They were evaluated byabdominal ultrasound (US) and NAFLD was defined in the presence of hepatic steatosis (US = Grades I to III).The occurrence of associated comorbidities, includingarterial hypertension, diabetes and dyslipidemia was recorded and the NCEP-ACT III criteria were applied to identify subjects with metabolic syndrome (MetS). DAS 28, BASDAI and ASDAS were used to assess PsA disease activity, while HAQ was performed to assess functional impairment. Student9s t, Chi-square and Fisher9s exact tests were performed for statistical analyses and P values ≤0.05 were considered significant. <h3>Results</h3> Fifty six PsA patients were initially enrolled, but 3 were excluded due to the presence of alcoholic cirrhosis in 2 and a positive serology for hepatitis C in 1. Among the remaining 53 patients, 26 were males and 27 females, with mean age = 54,8±13 yrs (27–76) and mean disease duration = 14,4±8,1 yrs (04–40). US revealed NAFLD in 33/53 (63%) patients with PsA, confirmed by liver biopsy in 2. Arterial hypertension, diabetes and dyslipidemia affected 81%, 42%, 75% of patients with NAFLD respectively (P&lt;0.001). MetS was present in 58,5% (31/53) individuals, significantly more prevalent in patients with compared to those without NAFLD: 26/33 (78.8%) vs. 05/20 (25.0%), P&lt;0.001, despite of gender. All disease activity indices (% patients with DAS28&gt;2.6), mean BASDAI and mean ASDAS) and HAQ scores were similar among patients with or without NAFLD (55.6% vs 46.7%; 3.1 vs 3.7; 1.9 vs 2.3; 1 vs 0.9 respectively, P&gt;0.05). <h3>Conclusions</h3> NAFLD is very common in our cohort of PsA patients occurring in over 2/3 regardless of disease activity and associated to MetS in most subjects, suggesting a relationship between these conditions. Moreover, screening for NAFLD inPsA patients is warranted in order to avoid increased overall liver morbidity. <h3>References</h3> Psoriatic arthritis: a systematic review, International Journal of Rheumatic Diseases 2010; 13: 300–317. Wenck et al. Journal of the European Academy of Dermatology, 2011. Candia et al. Journal of the European Academy of Dermatology, 2015. Di Minno et al. Arthritis Research &amp; Therapy, 2012. <h3>Disclosure of Interest</h3> None declared
Genomic Landscape Predictive of Minimal Residual Disease (MRD) in Multiple Myeloma (MM)
Authors: Mehmet K Samur, Stephane Minvielle, Florence Magrangeas, Giovanni Parmigiani, Kenneth C Anderson, Philippe Moreau, Michel Attal, Hervé Avet-Loiseau, Nikhil C. Munshi
Journal: Blood (2015)
Reduced-Intensity Conditioning of Allogeneic Transplantation for Nodal Peripheral T-Cell Lymphomas
Authors: Kazunari Aoki, Ritsuro Suzuki, Dai Chihara, Tatsuya Suzuki, Sung-Won Kim, Takahiro Fukuda, Naoyuki Uchida, Mitsuru Tsudo, Ken-ichi Matsuoka, Hiroatsu Ago, Tokiko Nagamura-Inoue, Yasuo Morishima, Hisashi Sakamaki, Yoshiko Atsuta, Junji Suzumiya
Journal: Blood (2014)
ABO In Morbidity and Mortality of Plasmodium Falciparum malaria
Authors: Christine Cserti-Gazdewich, Charles Musoke, Aggrey Dhabangi, Deborah Nakiboneka-Ssenabulya, Henry Ddungu, Nicolette Nabukeera-Barungi, Arthur Mpimbaza, Isaac Ssewanyana, Walter H Dzik
Journal: Blood (2010)
Maintenance of Earlier Hematopoietic Stem Cell (HSC) Phenotype and Improved NOD/SCID Engraftment for UCB Expanded Short-Term in Cytokines over a Human Mesenchymal Stem Cell (huMSC) Platform.
Authors: M. Kozik, J. Banks, L. Fanning, M. Finney, Y. Huang, O. Masri, S. Haynesworth, O. N. Koc, E. Szekely, K. Daum-Woods, M. J. Laughlin
Journal: Blood (2004)
Effect of Thrombotic Events on Overall Survival in Patients with Newly Diagnosed Myeloma: Analysis from a Randomized Phase III Trial of Thalidomide Plus Dexamethasone Versus Dexamethasone in Newly Diagnosed Multiple Myeloma (E1A00).
Authors: Shaji Kumar, Lijun Zhang, Philip R. Greipp, S. Vincent Rajkumar
Journal: Blood (2007)
Prospective Evaluation of the Prevalence of Elevated Tricuspid Regurgitant Jet Velocity and Associated Clinical and Echocardiographic Factors in Children and Adolescents with Sickle Cell Disease.
Authors: Andrew D. Campbell, Caterina Minniti, Craig Sable, Greg Ensing, Niti Dham, Sohail Rana, D. Darbari, Onyinye Onyekwere, Greg J. Kato, Mark T. Gladwin, Oswaldo Castro, Victor Gordeuk
Journal: Blood (2007)
A comprehensive musculoskeletal and peripheral nervous system assessment of war-related bilateral upper extremity amputees
Authors: Mostafa Allami, Batool Mousavi, Mehdi Masoumi, Ehsan Modirian, Hadi Shojaei, Fatemeh Mirsalimi, Maryam Hosseini, Pirouz Pirouzi
Journal: Military Medical Research (2016)

Upper limb amputations are one of the unpleasant war injuries that armed forces are exposed to frequently. The present study aimed to assess the musculoskeletal and peripheral nervous systems in Iraq-Iran war veterans with bilateral upper extremity amputation.The study consisted of taking a history and clinical examinations including demographic data, presence and location of pain, level of amputation, passive and active ranges of movement of the joints across the upper and lower extremities and spine, manual palpation, neurological examination, blood circulation pulses and issues related to a prosthetic limb. In this study, 103 Iranian bilateral upper extremity amputees (206 amputations) from the Iran-Iraq war were evaluated, and a detailed questionnaire was also administered.The most common level of amputation was the finger or wrist level (108, 52.4 %). Based on clinical examination, we found high frequencies of limited active and passive joint range of movement across the scapula, shoulder, elbow, wrist and metacarpophalangeal, interphalangeal and thumb joints. Based on muscle strength testing, we found varying degrees of weakness across the upper limbs. Musculoskeletal disorders included epicondylitis (65, 31.6 %), rotator cuff injury (24, 11.7 %), bicipital tendonitis (69, 33.5 %), shoulder drop (42, 20.4 %) and muscle atrophy (19, 9.2 %). Peripheral nerve disorders included carpal tunnel syndrome in 13 (6.3 %) and unilateral brachial plexus injury in 1 (1 %). Fifty-three (51.5 %) were diagnosed with facet joint syndrome at the level of the cervical spine (the most frequent site). Using a prosthesis was reported by 65 (63.1 %), both left and right sides. The back was the most common site of pain (71.8 %).The high prevalence of neuro-musculoskeletal disorders among bilateral upper extremity amputees indicates that they need regular rehabilitation care.
Limitations of G-CSF Mobilization in Splenectomized Patients with Beta-Thalassemia Major: Implications for Thalassemia Gene Therapy.
Authors: Evangelia Yannaki, Thalia Papayannopoulou, Erica Jonlin, Ioannis Batsis, Pamela S. Becker, Fani Zervou, Angeliki Xagorari, Garyfalia Karponi, Varvara Tahynopoulou, Panayotis Kaloyannidis, Varnavas Constantinou, Achilles Anagnostopoulos, Athanasios Fassas, George Stamatoyannopoulos
Journal: Blood (2009)